Tripeptidyl Peptidase II
Phone: +49 - 89 - 8578 2698
LBNL Berkeley, USA
Dr. Bing K. Jap & Dr. Peter J. Walian
LBNL Berkeley, USA
![]() |
Cytosolic protein degradation proceeds mainly via large, self-compartmentalized protein complexes burying their active sites in a secluded compartment. The paradigm for such a complex is the 26S proteasome, which degrades ubiquitinated proteins in an ATP-dependent manner. In the successive processing of the resulting, relatively small products, large complexes are also involved. One such large complex is tripeptidyl peptidase II (TPPII), an aminopeptidase of the subtilisin-type of serine proteases, which cleaves tripeptides from the free N-terminus of oligopeptides.
In recent years, TPPII has gained particular attention because of its up-regulation in mammalian cells in the presence of proteasome-inhibitors and its reported capability of substituting for some metabolic functions of the proteasome. In addition, TPPII has been implicated in the MHC class I processing, in diseases that are based on increased or uncontrolled proteolysis such as in septic muscles or in malignant cells, and recently also in fat-metabolism. A more specialized task is carried out by a membrane-bound TPPII variant, which inactivates cerebral neurotransmitters.
Having a molecular mass of 6 MDa, Drosophila TPPII is one of the largest eukaryotic protease complexes known. It is a 40-mer of 150 kDa subunits, which are assembled into a spindle-shaped 28 x 60-nm particle consisting of two segmented and twisted strands. This spindle structure of TPPII ensures high activity at high stability and presumably is the structural basis for self-compartmentalisation and protein-protein interactions.
We are interested in the molecular mechanism of TPPII and employ electron cryo-microscopy, xray-crystallography, biochemistry and molecular biology to solve its structure and to study its molecular interactions.